MedPath

Mobile Mindfulness Training for Smoking Cessation

Not Applicable
Completed
Conditions
Smoking Cessation
Registration Number
NCT02037360
Lead Sponsor
University of Massachusetts, Worcester
Brief Summary

The purpose of this study is to assess the effectiveness of a Mobile Mindfulness Training smartphone application on smoking cessation in smokers ages 18 to 65 years.

Detailed Description

In this study, a pilot phase will be carried out first to test feasibility and engagement of the tested intervention. Then in the randomized control trial, subjects will be randomly assigned to receive one of two treatments: (1) a standard smartphone application to support smokers working to become quit-free, or (2) the tested intervention, an app that trains mindfulness for smoking cessation. The primary endpoint of interest will be 1-week point prevalence abstinence at end of treatment, and at 3 and 6 months follow-up for individuals.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1251
Inclusion Criteria

Participants must be (a) 18-65 years of age; (b) smoke 5+ cigarettes/day, (c) < 3 months abstinence in the past year; (d) have a smartphone; and motivated to quit smoking.

Exclusion Criteria

There are no exclusion criteria. We aim to recruit a heterogeneous group, representative of the general population.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Point prevalence abstinence at 6 months6 months after beginning treatment

Subjects will be assessed for smoking abstinence at a 6-month follow-up.

Secondary Outcome Measures
NameTimeMethod
Point prevalence abstinence at 3 months3 months after beginning treatment

Subjects will be assessed for smoking abstinence at a 3-month follow-up.

Trial Locations

Locations (1)

University of Massachusetts, Worcester

🇺🇸

Worcester, Massachusetts, United States

University of Massachusetts, Worcester
🇺🇸Worcester, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.